Listing 1 - 10 of 10 |
Sort by
|
Choose an application
CD4+ T lymphocytes play an essential role in host defense against bacterial, parasitic and viral infections. During infection, under the influence of intrinsic signals received through peptide-MHC/TCR interactions and extrinsic signals provided by pathogen-conditioned dendritic and other accessory cells, CD4+ T cells proliferate and differentiate into specialized T helper (Th) effectors, which produce distinct sets of cytokines tailored to combat a specific class of microbes. The concept of CD4+ T cell multi-functionality was developed after the seminal discovery of Th1 and Th2 cells nearly 30 years ago. Although the Th1/Th2 paradigm has successfully withstood the test of time, in the past decade additional Th subsets (Th17, Tfh, Th22, Th9) have been identified. Similarly, single cell analyses of cytokines and master transcriptional factors have revealed that, at the population level, CD4+ T cell responses are far more heterogeneous than initially anticipated. While some of the checkpoints in Th cell specification have been identified, recent studies of transcriptional and epigenetic regulation have uncovered a significant flexibility during the course CD4+ T lymphocyte polarization. In addition, Th cells expressing cytokines with counteracting functions, as a measure of self-regulation, display yet another level of diversity. Understanding the mechanisms that control the balance between stability vs. plasticity of Th effectors both at the time of initiation of immune response and during development of CD4 T cell memory is critical for the rational design of better vaccines and new immunotherapeutic strategies. This research topic will cover current views on Th cell development, with a focus on the mechanisms that govern differentiation, function and regulation of effector Th cells in the context of microbial infections.
Clinical Immunology --- Medicine --- Health & Biological Sciences --- Infection --- Dendritic Cells --- Cytokines --- Immunoregulation --- CD4 lymphocytes --- Memory --- long noncoding RNA --- Macrophages --- Metabolism --- Th1 Th2
Choose an application
This book is a collection of eight articles, of which seven are reviews and one is a research paper, that together form a Special Issue that describes the roles that long noncoding RNAs (lncRNA) play in gene regulation at a post-transcriptional level.
long non-coding RNA 1 --- RNA binding protein 2 --- post-transcriptional regulation --- long non-coding RNA --- mRNA stability --- RNA binding protein --- microRNA --- gene expression --- long noncoding RNA --- target mimicry --- alternative splicing --- protein re-localization --- translation promotion --- post-translational modification --- double-stranded RNA (dsRNA) --- innate immunity --- repetitive DNA elements (RE) --- antisense transcript --- non-coding RNAs --- long non-coding RNAs --- ncRNAs --- translation --- cancer --- lncRNA --- post-transcription --- RNA-binding --- ribonucleoprotein --- RNAi --- interactome --- prediction --- database --- CLIP --- splicing factors --- miRNAs --- lncRNAs --- ceRNAs --- mTOR pathway --- n/a
Choose an application
MicroRNAs (miRNAs) are small noncoding RNAs that are 19–24 nucleotides in length, following maturation. Recent evidence has demonstrated their key role as post-transcriptional regulators of gene expression through the binding of specific sequences within target messenger RNA (mRNA). miRNAs are involved in the synthesis of a very large number of proteins, and it is speculated that they could regulate up to 30% of the human genome. They control virtually every cellular process and are essential for animal development, cell differentiation, and homeostasis. Altered miRNA expression has been linked to such pathological events as inflammatory, degenerative, or autoimmune processes and have been associated with several diseases, including cancer, cardiovascular diseases, diabetes mellitus, and rheumatic and neurological disorders. Recently, miRNAs have been found in many different biological fluids, and this observation suggests the potential of miRNAs as new candidate biomarkers for diagnosis, classification, prognosis, and responsiveness in the treatment of different pathological conditions. Furthermore, the development of therapeutic strategies that involve either restoring or repressing miRNAs expression and activity has attracted much attention. Significant progress has been made in the systems for delivery of miRNAs, even if substantial improvements in this area are still necessary. Although they have been extensively studied, a number of interesting questions regarding the physiological and pathological role of miRNAs have been postulated, and their potential diagnostic and therapeutic role remain yet unanswered. Reactive oxygen species (ROS) are free radical-containing oxygen molecules derived from cellular oxidative metabolism, including enzyme activities and mitochondrial respiration, and play a pivotal role in many cellular functions. Whereas ROS are essential for normal cellular processes, their aberrant production, or failure of the capacity to scavenge excessive ROS, induces an altered redox status with excessive synthesis of free radicals, leading to an imbalance in the redox environment of the cell. The loss of normal ROS levels causes lipid, protein, and DNA damage, which contribute to the development of various pathologies including neurological disorders, rheumatic and cardiovascular diseases, diabetes, and cancer. Increasing evidence highlights that there is crosstalk between miRNAs and components of redox signaling, even if this complex and the characteristics of mutual interaction need to be amply elucidated. Hence, both miRNAs and oxidative stress are involved in the multifactorial development and progression of acute and chronic diseases by influencing numerous signaling and metabolic pathways. The Special Issue entitled "Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology" of the International Journal of Molecular Sciences includes original articles and reviews that provide new insights into the interaction between miRNAs and oxidative stress under normal and pathological conditions which can assist in the development of new therapeutic strategies. Finally, I would like to thank all the authors for their excellent contribution. I hope this Special Issue will provide readers with updated knowledge about the role of miRNAs and oxidative stress in physiology and pathology.
Medicine --- miR-27a-5p --- acute myocardial infarction --- autophagy --- apoptosis --- hypoxia --- MicroRNA (miRNA) --- miR526b --- miR655 --- oxidative stress --- reactive oxygen species (ROS) --- superoxide (SO) --- Thioredoxin Reductase 1 (TXNRD1) --- breast cancer --- nucleic acid medicine --- pancreatic cancer --- clinical trial --- siRNA --- antisense oligonucleotide --- MicroRNA --- signal transduction --- therapeutic target --- miRNAs --- ROS --- noncoding RNA --- microRNA --- long noncoding RNA --- mitochondrial dysfunction --- nitrosative stress. exosome --- cross-talk --- systemic lupus erythematosus --- visfatin --- resistin --- osteoarthritis --- synovial fibroblasts --- synovitis --- NF-κB --- thyroid hormone --- liver cancer --- metabolism --- physiology --- ASH --- NAFLD --- NASH --- HCC --- HCV --- HBV --- endometriosis --- high-grade serous ovarian cancer --- endometriosis-associated ovarian cancer --- epithelial-to-mesenchymal transition --- chemoresistance --- antioxidants --- miRNA --- cancer --- diabetes --- beta cells --- microRNAs --- translation regulation --- neurodegeneration --- Alzheimer's disease --- Parkinson's disease --- Huntington's disease --- ALS --- reactive oxygen species --- redox signaling --- therapeutic tolerance --- therapeutic resistance --- miR-27a-5p --- acute myocardial infarction --- autophagy --- apoptosis --- hypoxia --- MicroRNA (miRNA) --- miR526b --- miR655 --- oxidative stress --- reactive oxygen species (ROS) --- superoxide (SO) --- Thioredoxin Reductase 1 (TXNRD1) --- breast cancer --- nucleic acid medicine --- pancreatic cancer --- clinical trial --- siRNA --- antisense oligonucleotide --- MicroRNA --- signal transduction --- therapeutic target --- miRNAs --- ROS --- noncoding RNA --- microRNA --- long noncoding RNA --- mitochondrial dysfunction --- nitrosative stress. exosome --- cross-talk --- systemic lupus erythematosus --- visfatin --- resistin --- osteoarthritis --- synovial fibroblasts --- synovitis --- NF-κB --- thyroid hormone --- liver cancer --- metabolism --- physiology --- ASH --- NAFLD --- NASH --- HCC --- HCV --- HBV --- endometriosis --- high-grade serous ovarian cancer --- endometriosis-associated ovarian cancer --- epithelial-to-mesenchymal transition --- chemoresistance --- antioxidants --- miRNA --- cancer --- diabetes --- beta cells --- microRNAs --- translation regulation --- neurodegeneration --- Alzheimer's disease --- Parkinson's disease --- Huntington's disease --- ALS --- reactive oxygen species --- redox signaling --- therapeutic tolerance --- therapeutic resistance
Choose an application
This book is a collection of eight articles, of which seven are reviews and one is a research paper, that together form a Special Issue that describes the roles that long noncoding RNAs (lncRNA) play in gene regulation at a post-transcriptional level.
Research & information: general --- Biology, life sciences --- long non-coding RNA 1 --- RNA binding protein 2 --- post-transcriptional regulation --- long non-coding RNA --- mRNA stability --- RNA binding protein --- microRNA --- gene expression --- long noncoding RNA --- target mimicry --- alternative splicing --- protein re-localization --- translation promotion --- post-translational modification --- double-stranded RNA (dsRNA) --- innate immunity --- repetitive DNA elements (RE) --- antisense transcript --- non-coding RNAs --- long non-coding RNAs --- ncRNAs --- translation --- cancer --- lncRNA --- post-transcription --- RNA-binding --- ribonucleoprotein --- RNAi --- interactome --- prediction --- database --- CLIP --- splicing factors --- miRNAs --- lncRNAs --- ceRNAs --- mTOR pathway --- long non-coding RNA 1 --- RNA binding protein 2 --- post-transcriptional regulation --- long non-coding RNA --- mRNA stability --- RNA binding protein --- microRNA --- gene expression --- long noncoding RNA --- target mimicry --- alternative splicing --- protein re-localization --- translation promotion --- post-translational modification --- double-stranded RNA (dsRNA) --- innate immunity --- repetitive DNA elements (RE) --- antisense transcript --- non-coding RNAs --- long non-coding RNAs --- ncRNAs --- translation --- cancer --- lncRNA --- post-transcription --- RNA-binding --- ribonucleoprotein --- RNAi --- interactome --- prediction --- database --- CLIP --- splicing factors --- miRNAs --- lncRNAs --- ceRNAs --- mTOR pathway
Choose an application
MicroRNAs (miRNAs) are small noncoding RNAs that are 19–24 nucleotides in length, following maturation. Recent evidence has demonstrated their key role as post-transcriptional regulators of gene expression through the binding of specific sequences within target messenger RNA (mRNA). miRNAs are involved in the synthesis of a very large number of proteins, and it is speculated that they could regulate up to 30% of the human genome. They control virtually every cellular process and are essential for animal development, cell differentiation, and homeostasis. Altered miRNA expression has been linked to such pathological events as inflammatory, degenerative, or autoimmune processes and have been associated with several diseases, including cancer, cardiovascular diseases, diabetes mellitus, and rheumatic and neurological disorders. Recently, miRNAs have been found in many different biological fluids, and this observation suggests the potential of miRNAs as new candidate biomarkers for diagnosis, classification, prognosis, and responsiveness in the treatment of different pathological conditions. Furthermore, the development of therapeutic strategies that involve either restoring or repressing miRNAs expression and activity has attracted much attention. Significant progress has been made in the systems for delivery of miRNAs, even if substantial improvements in this area are still necessary. Although they have been extensively studied, a number of interesting questions regarding the physiological and pathological role of miRNAs have been postulated, and their potential diagnostic and therapeutic role remain yet unanswered. Reactive oxygen species (ROS) are free radical-containing oxygen molecules derived from cellular oxidative metabolism, including enzyme activities and mitochondrial respiration, and play a pivotal role in many cellular functions. Whereas ROS are essential for normal cellular processes, their aberrant production, or failure of the capacity to scavenge excessive ROS, induces an altered redox status with excessive synthesis of free radicals, leading to an imbalance in the redox environment of the cell. The loss of normal ROS levels causes lipid, protein, and DNA damage, which contribute to the development of various pathologies including neurological disorders, rheumatic and cardiovascular diseases, diabetes, and cancer. Increasing evidence highlights that there is crosstalk between miRNAs and components of redox signaling, even if this complex and the characteristics of mutual interaction need to be amply elucidated. Hence, both miRNAs and oxidative stress are involved in the multifactorial development and progression of acute and chronic diseases by influencing numerous signaling and metabolic pathways. The Special Issue entitled "Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology" of the International Journal of Molecular Sciences includes original articles and reviews that provide new insights into the interaction between miRNAs and oxidative stress under normal and pathological conditions which can assist in the development of new therapeutic strategies. Finally, I would like to thank all the authors for their excellent contribution. I hope this Special Issue will provide readers with updated knowledge about the role of miRNAs and oxidative stress in physiology and pathology.
Medicine --- miR-27a-5p --- acute myocardial infarction --- autophagy --- apoptosis --- hypoxia --- MicroRNA (miRNA) --- miR526b --- miR655 --- oxidative stress --- reactive oxygen species (ROS) --- superoxide (SO) --- Thioredoxin Reductase 1 (TXNRD1) --- breast cancer --- nucleic acid medicine --- pancreatic cancer --- clinical trial --- siRNA --- antisense oligonucleotide --- MicroRNA --- signal transduction --- therapeutic target --- miRNAs --- ROS --- noncoding RNA --- microRNA --- long noncoding RNA --- mitochondrial dysfunction --- nitrosative stress. exosome --- cross-talk --- systemic lupus erythematosus --- visfatin --- resistin --- osteoarthritis --- synovial fibroblasts --- synovitis --- NF-κB --- thyroid hormone --- liver cancer --- metabolism --- physiology --- ASH --- NAFLD --- NASH --- HCC --- HCV --- HBV --- endometriosis --- high-grade serous ovarian cancer --- endometriosis-associated ovarian cancer --- epithelial-to-mesenchymal transition --- chemoresistance --- antioxidants --- miRNA --- cancer --- diabetes --- beta cells --- microRNAs --- translation regulation --- neurodegeneration --- Alzheimer’s disease --- Parkinson’s disease --- Huntington’s disease --- ALS --- reactive oxygen species --- redox signaling --- therapeutic tolerance --- therapeutic resistance --- n/a --- Alzheimer's disease --- Parkinson's disease --- Huntington's disease
Choose an application
This book provides important and updated information on current research devoted to urinary biomarkers. Urinary biomarkers are characteristics that can be objectively measured and evaluated as indicators of normal biological or pathogenic processes of pharmacological responses to therapeutic intervention.
Medicine --- poststreptococcal acute glomerulonephritis --- infection-related glomerulonephritis --- nephritis-associated plasmin receptor --- plasmin --- acute kidney injury --- renal biomarkers --- furosemide stress test --- functional assessment --- urine --- diabetic kidney disease --- kidney function --- proteomics --- mass spectrometry --- statistical clinical model --- machine learning --- acute tubulointerstitial nephritis --- immunology --- biomarkers --- chronic kidney disease --- differential diagnosis --- label-free quantification --- renal transplant --- extracellular vesicles --- acute rejection --- chronic rejection --- chronic allograft dysfunction --- calcineurin-inhibitor nephrotoxicity --- Polyomavirus associated nephropathy --- immunosuppression --- upper urinary tract obstruction --- kidney injury --- neutrophil gelatinase-associated lipocalin --- monocyte chemotactic protein-1 --- kidney injury molecule 1 --- cystatin C --- vanin-1 --- microRNA --- uromodulin --- kidney graft function --- biomarker --- kidney transplantation --- long noncoding RNA --- rejection --- microvascular injury --- urinary aminopeptidases --- arterial hypertension --- renal function --- urinary biomarkers --- markers of AKI --- cystatin-C --- NGAL --- KIM-1 --- exercise --- end-stage kidney disease (ESKD) --- cardiovascular disease --- epidemiology --- CKD --- macrophage subpopulation --- renal fibrosis --- trichostatin A --- kidney graft --- T-cell-mediated rejection --- antibody-mediated rejection --- diagnostic test accuracy --- gentamicin --- sepsis --- miRNA --- nephrotoxicity --- vancomycin --- n/a
Choose an application
MicroRNAs (miRNAs) are small noncoding RNAs that are 19–24 nucleotides in length, following maturation. Recent evidence has demonstrated their key role as post-transcriptional regulators of gene expression through the binding of specific sequences within target messenger RNA (mRNA). miRNAs are involved in the synthesis of a very large number of proteins, and it is speculated that they could regulate up to 30% of the human genome. They control virtually every cellular process and are essential for animal development, cell differentiation, and homeostasis. Altered miRNA expression has been linked to such pathological events as inflammatory, degenerative, or autoimmune processes and have been associated with several diseases, including cancer, cardiovascular diseases, diabetes mellitus, and rheumatic and neurological disorders. Recently, miRNAs have been found in many different biological fluids, and this observation suggests the potential of miRNAs as new candidate biomarkers for diagnosis, classification, prognosis, and responsiveness in the treatment of different pathological conditions. Furthermore, the development of therapeutic strategies that involve either restoring or repressing miRNAs expression and activity has attracted much attention. Significant progress has been made in the systems for delivery of miRNAs, even if substantial improvements in this area are still necessary. Although they have been extensively studied, a number of interesting questions regarding the physiological and pathological role of miRNAs have been postulated, and their potential diagnostic and therapeutic role remain yet unanswered. Reactive oxygen species (ROS) are free radical-containing oxygen molecules derived from cellular oxidative metabolism, including enzyme activities and mitochondrial respiration, and play a pivotal role in many cellular functions. Whereas ROS are essential for normal cellular processes, their aberrant production, or failure of the capacity to scavenge excessive ROS, induces an altered redox status with excessive synthesis of free radicals, leading to an imbalance in the redox environment of the cell. The loss of normal ROS levels causes lipid, protein, and DNA damage, which contribute to the development of various pathologies including neurological disorders, rheumatic and cardiovascular diseases, diabetes, and cancer. Increasing evidence highlights that there is crosstalk between miRNAs and components of redox signaling, even if this complex and the characteristics of mutual interaction need to be amply elucidated. Hence, both miRNAs and oxidative stress are involved in the multifactorial development and progression of acute and chronic diseases by influencing numerous signaling and metabolic pathways. The Special Issue entitled "Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology" of the International Journal of Molecular Sciences includes original articles and reviews that provide new insights into the interaction between miRNAs and oxidative stress under normal and pathological conditions which can assist in the development of new therapeutic strategies. Finally, I would like to thank all the authors for their excellent contribution. I hope this Special Issue will provide readers with updated knowledge about the role of miRNAs and oxidative stress in physiology and pathology.
miR-27a-5p --- acute myocardial infarction --- autophagy --- apoptosis --- hypoxia --- MicroRNA (miRNA) --- miR526b --- miR655 --- oxidative stress --- reactive oxygen species (ROS) --- superoxide (SO) --- Thioredoxin Reductase 1 (TXNRD1) --- breast cancer --- nucleic acid medicine --- pancreatic cancer --- clinical trial --- siRNA --- antisense oligonucleotide --- MicroRNA --- signal transduction --- therapeutic target --- miRNAs --- ROS --- noncoding RNA --- microRNA --- long noncoding RNA --- mitochondrial dysfunction --- nitrosative stress. exosome --- cross-talk --- systemic lupus erythematosus --- visfatin --- resistin --- osteoarthritis --- synovial fibroblasts --- synovitis --- NF-κB --- thyroid hormone --- liver cancer --- metabolism --- physiology --- ASH --- NAFLD --- NASH --- HCC --- HCV --- HBV --- endometriosis --- high-grade serous ovarian cancer --- endometriosis-associated ovarian cancer --- epithelial-to-mesenchymal transition --- chemoresistance --- antioxidants --- miRNA --- cancer --- diabetes --- beta cells --- microRNAs --- translation regulation --- neurodegeneration --- Alzheimer’s disease --- Parkinson’s disease --- Huntington’s disease --- ALS --- reactive oxygen species --- redox signaling --- therapeutic tolerance --- therapeutic resistance --- n/a --- Alzheimer's disease --- Parkinson's disease --- Huntington's disease
Choose an application
This book provides important and updated information on current research devoted to urinary biomarkers. Urinary biomarkers are characteristics that can be objectively measured and evaluated as indicators of normal biological or pathogenic processes of pharmacological responses to therapeutic intervention.
poststreptococcal acute glomerulonephritis --- infection-related glomerulonephritis --- nephritis-associated plasmin receptor --- plasmin --- acute kidney injury --- renal biomarkers --- furosemide stress test --- functional assessment --- urine --- diabetic kidney disease --- kidney function --- proteomics --- mass spectrometry --- statistical clinical model --- machine learning --- acute tubulointerstitial nephritis --- immunology --- biomarkers --- chronic kidney disease --- differential diagnosis --- label-free quantification --- renal transplant --- extracellular vesicles --- acute rejection --- chronic rejection --- chronic allograft dysfunction --- calcineurin-inhibitor nephrotoxicity --- Polyomavirus associated nephropathy --- immunosuppression --- upper urinary tract obstruction --- kidney injury --- neutrophil gelatinase-associated lipocalin --- monocyte chemotactic protein-1 --- kidney injury molecule 1 --- cystatin C --- vanin-1 --- microRNA --- uromodulin --- kidney graft function --- biomarker --- kidney transplantation --- long noncoding RNA --- rejection --- microvascular injury --- urinary aminopeptidases --- arterial hypertension --- renal function --- urinary biomarkers --- markers of AKI --- cystatin-C --- NGAL --- KIM-1 --- exercise --- end-stage kidney disease (ESKD) --- cardiovascular disease --- epidemiology --- CKD --- macrophage subpopulation --- renal fibrosis --- trichostatin A --- kidney graft --- T-cell-mediated rejection --- antibody-mediated rejection --- diagnostic test accuracy --- gentamicin --- sepsis --- miRNA --- nephrotoxicity --- vancomycin --- n/a
Choose an application
This book provides important and updated information on current research devoted to urinary biomarkers. Urinary biomarkers are characteristics that can be objectively measured and evaluated as indicators of normal biological or pathogenic processes of pharmacological responses to therapeutic intervention.
Medicine --- poststreptococcal acute glomerulonephritis --- infection-related glomerulonephritis --- nephritis-associated plasmin receptor --- plasmin --- acute kidney injury --- renal biomarkers --- furosemide stress test --- functional assessment --- urine --- diabetic kidney disease --- kidney function --- proteomics --- mass spectrometry --- statistical clinical model --- machine learning --- acute tubulointerstitial nephritis --- immunology --- biomarkers --- chronic kidney disease --- differential diagnosis --- label-free quantification --- renal transplant --- extracellular vesicles --- acute rejection --- chronic rejection --- chronic allograft dysfunction --- calcineurin-inhibitor nephrotoxicity --- Polyomavirus associated nephropathy --- immunosuppression --- upper urinary tract obstruction --- kidney injury --- neutrophil gelatinase-associated lipocalin --- monocyte chemotactic protein-1 --- kidney injury molecule 1 --- cystatin C --- vanin-1 --- microRNA --- uromodulin --- kidney graft function --- biomarker --- kidney transplantation --- long noncoding RNA --- rejection --- microvascular injury --- urinary aminopeptidases --- arterial hypertension --- renal function --- urinary biomarkers --- markers of AKI --- cystatin-C --- NGAL --- KIM-1 --- exercise --- end-stage kidney disease (ESKD) --- cardiovascular disease --- epidemiology --- CKD --- macrophage subpopulation --- renal fibrosis --- trichostatin A --- kidney graft --- T-cell-mediated rejection --- antibody-mediated rejection --- diagnostic test accuracy --- gentamicin --- sepsis --- miRNA --- nephrotoxicity --- vancomycin --- poststreptococcal acute glomerulonephritis --- infection-related glomerulonephritis --- nephritis-associated plasmin receptor --- plasmin --- acute kidney injury --- renal biomarkers --- furosemide stress test --- functional assessment --- urine --- diabetic kidney disease --- kidney function --- proteomics --- mass spectrometry --- statistical clinical model --- machine learning --- acute tubulointerstitial nephritis --- immunology --- biomarkers --- chronic kidney disease --- differential diagnosis --- label-free quantification --- renal transplant --- extracellular vesicles --- acute rejection --- chronic rejection --- chronic allograft dysfunction --- calcineurin-inhibitor nephrotoxicity --- Polyomavirus associated nephropathy --- immunosuppression --- upper urinary tract obstruction --- kidney injury --- neutrophil gelatinase-associated lipocalin --- monocyte chemotactic protein-1 --- kidney injury molecule 1 --- cystatin C --- vanin-1 --- microRNA --- uromodulin --- kidney graft function --- biomarker --- kidney transplantation --- long noncoding RNA --- rejection --- microvascular injury --- urinary aminopeptidases --- arterial hypertension --- renal function --- urinary biomarkers --- markers of AKI --- cystatin-C --- NGAL --- KIM-1 --- exercise --- end-stage kidney disease (ESKD) --- cardiovascular disease --- epidemiology --- CKD --- macrophage subpopulation --- renal fibrosis --- trichostatin A --- kidney graft --- T-cell-mediated rejection --- antibody-mediated rejection --- diagnostic test accuracy --- gentamicin --- sepsis --- miRNA --- nephrotoxicity --- vancomycin
Choose an application
This book describes translational cancer therapeutics and the way forward from clinical and molecular diagnosis to treatment. In addition, genomics alterations, microRNAs, and long non-coding RNAs translate precision medicine for the individualistic therapy of cancer patients. It describes the involvement of various pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines. Indeed, the role of bioinformatics and biostatistics, considering the extensive data analysis serving precision medicine approaches, has also been entertained in the present book. Therefore, intended book demonstrates the successful medical evidence for the use of precision medicine in the treatment of cancer and its future clinical perspectives. It fills the gaps in cancer biology and precision medicine with its up-to-date content and well-designed chapters. It will serve as a valuable resource for science, medical students, and interdisciplinary researchers. It is a very welcome addition for the scientific community, research centers, and university-industry research collaborators to find out a complete capsular package about cancer drug targets, precision, and personalized medicine (including an introduction to cancer cell signaling, genomic alterations, miRNA targeting, pharmacogenetics, biomarkers, and metabolomics in precision medicine, etc.) at a single platform.
Precision Medicine. --- Pharmacogenetics. --- Pharmacogenomic Variants. --- MicroRNAs --- RNA, Long Noncoding. --- Biomarkers. --- Neoplasms --- Medical Oncology. --- therapy. --- Clinical Oncology --- Oncology, Medical --- Oncology, Clinical --- Biochemical Marker --- Biologic Marker --- Biologic Markers --- Clinical Marker --- Immune Marker --- Immune Markers --- Immunologic Marker --- Laboratory Marker --- Marker, Biochemical --- Marker, Biological --- Marker, Clinical --- Marker, Immunologic --- Marker, Laboratory --- Marker, Serum --- Marker, Surrogate --- Serum Marker --- Surrogate End Point --- Surrogate End Points --- Surrogate Endpoint --- Surrogate Endpoints --- Surrogate Marker --- Viral Marker --- Biochemical Markers --- Biological Markers --- Biomarker --- Clinical Markers --- Immunologic Markers --- Laboratory Markers --- Markers, Biochemical --- Markers, Biological --- Markers, Clinical --- Markers, Immunologic --- Markers, Laboratory --- Markers, Serum --- Markers, Surrogate --- Markers, Viral --- Serum Markers --- Surrogate Markers --- Viral Markers --- Biological Marker --- End Point, Surrogate --- End Points, Surrogate --- Endpoint, Surrogate --- Endpoints, Surrogate --- Marker, Biologic --- Marker, Immune --- Marker, Viral --- Markers, Biologic --- Markers, Immune --- Molecular Probes --- Endophenotypes --- LINC RNA --- LincRNAs --- Long Intergenic Non-Protein Coding RNA --- Long Non-Coding RNA --- Long Non-Protein-Coding RNA --- Long Noncoding RNA --- Long ncRNA --- Long ncRNAs --- RNA, Long Non-Translated --- lncRNA --- LincRNA --- RNA, Long Untranslated --- Long Intergenic Non Protein Coding RNA --- Long Non Coding RNA --- Long Non Protein Coding RNA --- Long Non-Translated RNA --- Long Untranslated RNA --- Non-Coding RNA, Long --- Non-Protein-Coding RNA, Long --- Non-Translated RNA, Long --- Noncoding RNA, Long --- RNA, Long Non Translated --- RNA, Long Non-Coding --- RNA, Long Non-Protein-Coding --- Untranslated RNA, Long --- ncRNA, Long --- ncRNAs, Long --- Micro RNA --- MicroRNA --- Primary MicroRNA --- Primary miRNA --- miRNAs --- pre-miRNA --- pri-miRNA --- RNA, Small Temporal --- Small Temporal RNA --- miRNA --- stRNA --- MicroRNA, Primary --- RNA, Micro --- Temporal RNA, Small --- miRNA, Primary --- pre miRNA --- pri miRNA --- RNA, Small Interfering --- Pharmacogenetic Variants --- Pharmacokinetic Genetic Variants --- Genetic Variant, Pharmacokinetic --- Genetic Variants, Pharmacokinetic --- Pharmacogenetic Variant --- Pharmacogenomic Variant --- Pharmacokinetic Genetic Variant --- Variant, Pharmacogenetic --- Variant, Pharmacogenomic --- Variants, Pharmacogenetic --- Variants, Pharmacogenomic --- Pharmacogenetics --- Precision Medicine --- P Health --- P-Health --- Personalized Medicine --- Theranostics --- Individualized Medicine --- Predictive Medicine --- Medicine, Individualized --- Medicine, Personalized --- Medicine, Precision --- Medicine, Predictive --- Theranostic --- Pharmacogenomic Variants --- Patient-Specific Modeling --- Pharmacogenomics --- Drug Resistance --- Toxicology --- Cancer. --- Cancer—Genetic aspects. --- Oncology. --- Therapeutics. --- Cancer Biology. --- Cancer Genetics and Genomics. --- Medical treatment --- Therapy --- Treatment of diseases --- Treatments for diseases --- Clinical medicine --- Tumors --- Cancers --- Carcinoma --- Malignancy (Cancer) --- Malignant tumors
Listing 1 - 10 of 10 |
Sort by
|